Immunome, Inc. (IMNM) shares soared 6.1% in the last trading session to close at $11.2. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.9% gain over the past four weeks.The sudden price rise can be attributed to growing investor optimism regarding the company’s efforts to develop its lead pipeline candidate, varegacestat, which is currently being evaluated in a late-stage study for the treatment of desmoid tumors. Immunome is a ...

股价表现 - Immunome Inc (IMNM) 股价在上一交易日上涨6%至9.3美元 成交量显著高于平均水平 [1] - 过去四周该股累计涨幅仅为0.1% 此次单日涨幅明显扩大 [1] - 同行业公司Nurix Therapeutics (NRIX) 同期下跌2.2%至11.39美元 但过去一个月累计上涨9.5% [5] 股价驱动因素 - 投资者对公司主导管线药物varegacestat持乐观态度 该药物正处于治疗硬纤维瘤的后期临床研究阶段 [2] - 公司还在开发其他针对多种癌症适应症的靶向治疗药物 目前处于早期研究阶段 [2] - 季度每股收益预期在过去30天内上调1.9% 盈利预期修正趋势与股价走势呈现正相关 [4] 财务预期 - 预计季度每股亏损0.52美元 同比恶化6.1% [3] - 预计季度收入247万美元 同比增长4.5% [3] - 同行业公司Nurix Therapeutics预计季度每股亏损0.72美元 同比恶化1.4% [6] 行业评级 - Immunome和Nurix Therapeutics均获得Zacks Rank 3(持有)评级 [5][6] - 两家公司同属Zacks医疗-生物医学和遗传学行业 [5]